Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda

The malaria vaccine BK-SE36 is a recombinant protein (SE36) based on the Honduras 1 serine repeat antigen-5 of Plasmodium falciparum, adsorbed to aluminium hydroxide gel. The phase Ib trial in Uganda demonstrated the safety and immunogenicity of BK-SE36. Ancillary analysis in the follow-up study of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yagi, Masanori, Palacpac, Nirianne M. Q., Ito, Kazuya, Oishi, Yuko, Itagaki, Sawako, Balikagala, Betty, Ntege, Edward H., Yeka, Adoke, Kanoi, Bernard N., Katuro, Osbert, Shirai, Hiroki, Fukushima, Wakaba, Hirota, Yoshio, Egwang, Thomas G., Horii, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050508/
https://www.ncbi.nlm.nih.gov/pubmed/27703240
http://dx.doi.org/10.1038/srep34363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050508/
https://www.ncbi.nlm.nih.gov/pubmed/27703240
http://dx.doi.org/10.1038/srep34363

Ejemplares similares